RT Book, Section
A1 Giuliano, Armando E.
A1 Hurvitz, Sara A.
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1184174934
T1 Carcinoma of the Female Breast
T2 Current Medical Diagnosis & Treatment 2022
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264269389
LK accessmedicine.mhmedical.com/content.aspx?aid=1184174934
RD 2024/04/18
AB KEY  CLINICAL  UPDATES  IN  CARCINOMA  OF  THE  FEMALE  BREASTIn  2020,  the  FDA  approved  neratinib  (in  combination  with  capecitabine)  and  margetuximab,  a  monoclonal  antibody  similar  to  trastuzumab  that  is  designed  to  improve  the  antibody  dependent  cellular  cytotoxicity  mechanism  of  action  when  used  with  chemotherapy.In  2020,  pembrolizumab,  a  second  immune  checkpoint  inhibitor,  was  FDA  approved  for  use  in  patients  with  PD-L1  positive  disease  in  combination  with  chemotherapy  (taxane  or  gemcitabine/carboplatin)  based  on  results  from  the  KEYNOTE  355  trial  showing  an  improved  median  progression-free  survival  with  the  addition  of  this  antibody  to  standard  chemotherapy.Sacituzumab  govitecan  (TRODELVY)  is  the  first  antibody  drug  conjugate  approved  for  triple  negative  breast  cancer.The  phase  3  confirmatory  trial,  ASCENT,  demonstrated  that  sacituzumab  govitecan  is  associated  with  a  statistically  significant  improvement  in  progression-free  and  overall  survival  when  compared  to  single-agent  chemotherapy  in  patients  with  triple  negative  breast  cancer  who  had  received  at  least  two  prior  lines  of  standard  chemotherapy  for  metastatic  disease.